<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Elevated hepatic lipase (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, also known as LIPC) expression is a key factor in the development of the atherogenic <z:chebi fb="23" ids="18059">lipid</z:chebi> profile in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, genetic screens revealed a possible association of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0020474,C1704417" disease_type="Disease or Syndrome" abbrv="">familial combined hyperlipidaemia</z:e> with the USF1 gene </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we investigated the role of upstream stimulatory factors (USFs) in the regulation of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Levels of USF1, USF2 and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> were measured in HepG2 cells cultured in <z:mpath ids='MPATH_458'>normal</z:mpath>- or high-<z:chebi fb="105" ids="17234">glucose</z:chebi> medium (4.5 and 22.5 mmol/l, respectively) and in livers of <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-treated rats </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Nuclear extracts of cells cultured in high <z:chebi fb="105" ids="17234">glucose</z:chebi> contained 2.5 +/- 0.5-fold more USF1 and 1.4 +/- 0.2-fold more USF2 protein than cells cultured in <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> (mean +/- SD, n = 3) </plain></SENT>
<SENT sid="5" pm="."><plain>This coincided with higher DNA binding of nuclear proteins to the USF consensus DNA binding site </plain></SENT>
<SENT sid="6" pm="."><plain>Secretion of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> (2.9 +/- 0.5-fold), abundance of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> <z:chebi fb="2" ids="33699">mRNA</z:chebi> (1.5 +/- 0.2-fold) and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> (-685/+13) promoter activity (1.8 +/- 0.3-fold) increased in parallel </plain></SENT>
<SENT sid="7" pm="."><plain>In chromatin immunoprecipitation assays, the proximal <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> promoter region was immunoprecipitated with anti-USF1 and anti-USF2 antibodies </plain></SENT>
<SENT sid="8" pm="."><plain>Co-transfection with USF1 or USF2 cDNA stimulated <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> promoter activity 6- to 16-fold </plain></SENT>
<SENT sid="9" pm="."><plain>USF and <z:chebi fb="105" ids="17234">glucose</z:chebi> responsiveness were significantly reduced by removal of the -310E-box from the <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> promoter </plain></SENT>
<SENT sid="10" pm="."><plain>Silencing of the USF1 gene by <z:chebi fb="40" ids="33697">RNA</z:chebi> interference reduced <z:chebi fb="105" ids="17234">glucose</z:chebi> responsiveness of the <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> (-685/+13) promoter region by 50% </plain></SENT>
<SENT sid="11" pm="."><plain>The <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-treated rats was associated with similar increases in USF abundance in rat liver nuclei, but not with increased binding of USF to the rat Hl promoter region </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS/INTERPRETATION: <z:chebi fb="105" ids="17234">Glucose</z:chebi> increases <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> expression in HepG2 cells via elevation of USF1 and USF2 </plain></SENT>
<SENT sid="13" pm="."><plain>This mechanism may contribute to the development of the <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> that is typical of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>